Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 · kind B2 · utility
11Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2007 |
| Grant date | Nov 18, 2008 |
| Priority date | — |
| Expiry date | May 31, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention encompasses compounds as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.